{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:08:42Z","timestamp":1766182122440,"version":"3.41.0"},"reference-count":103,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015078","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T12:22:21Z","timestamp":1690287741000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiplatelet agents for the treatment of adults with COVID-19"],"prefix":"10.1002","volume":"2023","author":[{"given":"Anna-Lena","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Intensive care; Universit\u00e4tsklinikum Leipzig; 04103 Leipzig Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Messer","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Riera","sequence":"additional","affiliation":[{"name":"Cochrane Brazil Rio de Janeiro; Cochrane; Petr\u00f3polis Brazil"},{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias, Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade e Edua\u00e7\u00e3o em Sa\u00fade (NEP-Sbeats); Universidade Federal de S\u00e3o Paulo (Unifesp); S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Luiza C","family":"Martimbianco","sequence":"additional","affiliation":[{"name":"Cochrane Brazil Rio de Janeiro; Cochrane; Petr\u00f3polis Brazil"},{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"Universidade Metropolitana de Santos (UNIMES); Santos Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Stegemann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Weibel","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital Wuerzburg; Wuerzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marike","family":"Andreas","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael L","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias, Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade e Edua\u00e7\u00e3o em Sa\u00fade (NEP-Sbeats); Universidade Federal de S\u00e3o Paulo (Unifesp); S\u00e3o Paulo Brazil"},{"name":"Centro de Pesquisa M\u00e9dica; Centro Universit\u00e1rio S\u00e3o Camilo (CUSC); S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD015078-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 inhibitors on survival free of organ support among non\u2013critically ill hospitalized patients with COVID-19: a randomized clinical trial","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015078-BIB0002|cit2","unstructured":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A) clinicaltrials.gov\/ct2\/show\/NCT04505774"},{"key":"10.1002\/14651858.CD015078-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1344\u201356","DOI":"10.1161\/CIRCULATIONAHA.122.061533","article-title":"Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: (COVID-PACT)","volume":"146","author":"Bohula","year":"2022","journal-title":"Circulation"},{"issue":"17","key":"10.1002\/14651858.CD015078-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: The ACTIV-4B randomized clinical trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015078-BIB0005|cit5","unstructured":"COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 clinicaltrials.gov\/ct2\/show\/NCT04498273"},{"issue":"12","key":"10.1002\/14651858.CD015078-BIB0006|cit6","first-page":"1160\u20138","article-title":"Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial","volume":"10","author":"Eikelboom","year":"2022","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD015078-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2021.06.08.21258132","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"June 8","author":"Horby","year":"2021","journal-title":"medRxiv"},{"key":"10.1002\/14651858.CD015078-BIB0008|cit8","first-page":"1","article-title":"Aspirin in patients admitted to hospital with COVID-19(RECOVERY): a randomised, controlled, open-label, platform trial","volume":"Published Onlin","author":"Horby","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD015078-BIB0009|cit9","unstructured":"Randomised Evaluation of COVID-19 Therapy (RECOVERY) clinicaltrials.gov\/ct2\/show\/NCT04381936"},{"key":"10.1002\/14651858.CD015078-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"143 to 151","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"RECOVERY Collaborative Group","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015078-BIB0011|cit11","unstructured":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP) clinicaltrials.gov\/ct2\/show\/NCT02735707"},{"key":"10.1002\/14651858.CD015078-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"13","author":"REMAP-CAP Writing Committee for the REMAP-CAP Investigators","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD015078-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2022.23257","article-title":"Long-term (180-Day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial","volume":"329","author":"REMAP-CAP Writing Committee for the REMAP-CAP Investigators","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015078-BIB0014|cit14","first-page":"1169\u201377","article-title":"Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label,factorial, randomised, controlled trial","volume":"10","author":"Eikelboom","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD015078-BIB0015|cit15","unstructured":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT ADAPT) clinicaltrials.gov\/ct2\/show\/NCT04483960"},{"key":"10.1002\/14651858.CD015078-BIB0016|cit16","unstructured":"Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 clinicaltrials.gov\/ct2\/show\/study\/NCT04391179"},{"key":"10.1002\/14651858.CD015078-BIB0017|cit17","unstructured":"Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 (GARDEN) clinicaltrials.gov\/ct2\/show\/NCT04659109"},{"key":"10.1002\/14651858.CD015078-BIB0018|cit18","unstructured":"Statin and aspirin in SARS-CoV-2 infection ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=44814"},{"key":"10.1002\/14651858.CD015078-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Ghati N Deepti S Bhatnagar S Mahendran M Thakur A Prasad K A randomised control trial of statin and aspirin as adjuvant therapy in patients with SARS-CoV-2 infection (RESIST Trial) SSRN 2021 10.2139\/ssrn.3820512","DOI":"10.1186\/s12879-022-07570-5"},{"key":"10.1002\/14651858.CD015078-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1186\/s13063-020-04840-y","article-title":"Atorvastatin and aspirin as adjuvant therapy in patients with SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Ghati","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015078-BIB0021|cit21","unstructured":"Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showprojen.aspx?proj=49864"},{"key":"10.1002\/14651858.CD015078-BIB0022|cit22","unstructured":"Low Dose Aspirin in Moderate to Severe SARS- CoV-2 Infected Patients: A Pilot Randomized Controlled Trial ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=44980"},{"key":"10.1002\/14651858.CD015078-BIB0023|cit23","unstructured":"Investigator initiated study to evaluate the effect of Marketed Colchicine 0.5mg given along marketed Asprin 75mg with SOC and Marketed aspirin 75mg with SOC on COVID 19 patients ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=53115"},{"key":"10.1002\/14651858.CD015078-BIB0024|cit24","unstructured":"Randomized controlled clinical trial to assess the efficacy and safety of APMV2020 in mildsymptomatic subjects of COVID 19 ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=56647"},{"key":"10.1002\/14651858.CD015078-BIB0025|cit25","unstructured":"The investigation of the effectiveness of ASA usage on the incidence of cardiovascular events in patients with corona virus (COVID-19) A clinical trial study en.irct.ir\/trial\/52374"},{"key":"10.1002\/14651858.CD015078-BIB0026|cit26","unstructured":"The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations (LEAD COVID-19) clinicaltrials.gov\/ct2\/show\/NCT04363840"},{"key":"10.1002\/14651858.CD015078-BIB0027|cit27","unstructured":"Protective Effect of Aspirin on COVID-19 Patients (PEAC) clinicaltrials.gov\/ct2\/show\/NCT04365309"},{"key":"10.1002\/14651858.CD015078-BIB0028|cit28","unstructured":"Prasugrel in Severe COVID-19 Pneumonia (PARTISAN) clinicaltrials.gov\/ct2\/show\/NCT04445623"},{"key":"10.1002\/14651858.CD015078-BIB0029|cit29","unstructured":"Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia (PaTS-COVID) www.clinicaltrials.gov\/ct2\/show\/NCT04703608"},{"key":"10.1002\/14651858.CD015078-BIB0030|cit30","unstructured":"Safety & Efficacy of Low Dose Aspirin \/ Ivermectin Combination Therapy for Treatment of Covid-19 Patients (IVCOM) clinicaltrials.gov\/ct2\/show\/NCT04768179"},{"key":"10.1002\/14651858.CD015078-BIB0031|cit31","unstructured":"Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19 (Asperum) clinicaltrials.gov\/ct2\/show\/NCT04808895"},{"key":"10.1002\/14651858.CD015078-BIB0032|cit32","unstructured":"Outpatient Liquid Aspirin (OLA) (OLA COVID) clinicaltrials.gov\/ct2\/show\/NCT04937088"},{"key":"10.1002\/14651858.CD015078-BIB0033|cit33","unstructured":"Acetylsalicylic Acid in COVID-19 (ASA-SARS) clinicaltrials.gov\/ct2\/show\/NCT05073718"},{"key":"10.1002\/14651858.CD015078-BIB0034|cit34","unstructured":"Study to access effectiveness of new drug therapy (aspirin,atorvastatin and nicorandil) in covid-19 trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/04\/032648"},{"issue":"451","key":"10.1002\/14651858.CD015078-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-021-05361-y","article-title":"A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial","volume":"22","author":"Sharma","year":"2021","journal-title":"Trials"},{"issue":"6","key":"10.1002\/14651858.CD015078-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jiph.2022.05.003.","article-title":"Venous and arterial thrombosis in COVID-19: An updated narrative review","volume":"15","author":"Al Duhailib","journal-title":"Journal of Infection and Public Health"},{"issue":"10","key":"10.1002\/14651858.CD015078-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"101292","DOI":"10.1016\/j.cpcardiol.2022.101292","article-title":"P2Y12 inhibitors versus aspirin monotherapy for long-term secondary prevention of atherosclerotic cardiovascular disease events: A systematic review and meta-analysis","volume":"47","author":"Al-Abdouh","year":"2022","journal-title":"Current Problems in Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD015078-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.cir.101.10.1206","article-title":"Aspirin","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"issue":"56","key":"10.1002\/14651858.CD015078-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01365-2020","article-title":"Pulmonary embolism in patients with COVID-19 pneumonia","volume":"56","author":"Bompard","journal-title":"European Respiratory Journal"},{"issue":"9","key":"10.1002\/14651858.CD015078-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","article-title":"Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis","volume":"17","author":"Buitrago-Garcia","year":"2020","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD015078-BIB0041|cit41","unstructured":"CEOsys: Living evidence synthesis as the basis for decisions in the COVID-19 pandemic covid-evidenz.de\/what-is-ceosys\/"},{"key":"10.1002\/14651858.CD015078-BIB0042|cit42","unstructured":"Core outcome set developers\u2019 response to COVID-19 Available from www.comet-initiative.org\/Studies\/Details\/1538"},{"key":"10.1002\/14651858.CD015078-BIB0043|cit43","first-page":"1513","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21","volume":"S0140-6736(21)0","author":"COVID-19 Excess Mortality Collaborators","journal-title":"Lancet"},{"issue":"18","key":"10.1002\/14651858.CD015078-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/jth.14830","article-title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia","volume":"18","author":"Cui","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD015078-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e89S","DOI":"10.1378\/chest.11-2293","article-title":"Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Eikelboom","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD015078-BIB0046|cit46","unstructured":"EndNote X9 The EndNote Team Clarivate 2013"},{"issue":"3","key":"10.1002\/14651858.CD015078-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013881","article-title":"Interleukin-6 blocking agents for treating COVID-19: a living systematic review","author":"Ghosn","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015078-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014962","article-title":"Remdesivir for the treatment of COVID-19","author":"Grundeis","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD015078-BIB0049|cit49","first-page":"192","article-title":"Chemical structures and mode of action of intravenous glycoprotein IIb\/IIIa receptor blockers: A review","volume":"13","author":"Hashemzadeh","year":"2008","journal-title":"Journal of Clinical and Experimental Cardiology"},{"key":"10.1002\/14651858.CD015078-BIB0050|cit50","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page M J Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) Available from: training.cochrane.org\/handbook 2021"},{"key":"10.1002\/14651858.CD015078-BIB0051|cit51","unstructured":"Higgins JP Savovic\u0301 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021) Available from training.cochrane.org\/handbook 2021"},{"key":"10.1002\/14651858.CD015078-BIB0052|cit52","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015078-BIB0053|cit53","unstructured":"Higgins JP Tianging L Deeks J J Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated September 2021) Available from training.cochrane.org\/handbook 2021"},{"key":"10.1002\/14651858.CD015078-BIB0054|cit54","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"10223","key":"10.1002\/14651858.CD015078-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD015078-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub5","article-title":"Convalescent plasma for people with COVID-19: a living systematic review","author":"Iannizzi","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015078-BIB0057|cit57","unstructured":"Johns Hopkins University & Medicine Coronavirus Resource Center Mortality analyses Available from coronavirus.jhu.edu\/data\/mortality"},{"issue":"10","key":"10.1002\/14651858.CD015078-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrcardio.2011.128","article-title":"Managing adverse effects and drug-drug interactions of antiplatelet agents","volume":"8","author":"Kalyanasundaram","year":"2011","journal-title":"Nature Reviews Cardiology"},{"key":"10.1002\/14651858.CD015078-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/bmj-2021-069590","article-title":"Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study","volume":"e069590","author":"Katsoularis","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015078-BIB0060|cit60","first-page":"1425","article-title":"Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis","volume":"142(15)","author":"Khan","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD015078-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis","volume":"191","author":"Klok","year":"2020","journal-title":"Thrombosis Research"},{"issue":"6","key":"10.1002\/14651858.CD015078-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015209","article-title":"Janus kinase inhibitors for the treatment of COVID-19","author":"Kramer","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015078-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013825.pub2","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015078-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/VHRM.S2691","article-title":"Antiplatelet drugs in cardiological practice: established strategies and new developments","volume":"4","author":"Kr\u00f6tz","year":"2008","journal-title":"Vascular Health and Risk Management"},{"issue":"2","key":"10.1002\/14651858.CD015078-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1471-4892(03)00007-9","article-title":"Platelet purinergic receptors","volume":"3","author":"Kunapuli","journal-title":"Elsevier"},{"issue":"9","key":"10.1002\/14651858.CD015078-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"577\u201382","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015078-BIB0067|cit67","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD015078-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015078-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s13054-020-03175-z","article-title":"Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis","volume":"24","author":"Liao","year":"2020","journal-title":"Critical Care"},{"key":"10.1002\/14651858.CD015078-BIB0070|cit70","unstructured":"MAGICapp Norwegian MAGIC Evidence Ecosystem Foundation (powered by UserVoice Inc.) 2020"},{"issue":"8","key":"10.1002\/14651858.CD015078-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD015078-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/his.14134","article-title":"Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction","volume":"77","author":"Menter","journal-title":"Histopathology"},{"key":"10.1002\/14651858.CD015078-BIB0073|cit73","unstructured":"Mircosoft Excel Microsoft Corporation 2018"},{"key":"10.1002\/14651858.CD015078-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Middeldorp","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1(1)","key":"10.1002\/14651858.CD015078-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000029.pub4","article-title":"Oral antiplatelet therapy for acute ischaemic stroke","author":"Minhas","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD015078-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015078-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"e001549","DOI":"10.1136\/rmdopen-2020-001549","article-title":"Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider","volume":"7","author":"Najm","year":"2021","journal-title":"RMD Open"},{"issue":"2","key":"10.1002\/14651858.CD015078-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"e0246825","DOI":"10.1371\/journal.pone.0246825","article-title":"Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration","volume":"16","author":"Osborne","year":"2021","journal-title":"PLoS One"},{"issue":"24","key":"10.1002\/14651858.CD015078-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8.","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015078-BIB0080|cit80","unstructured":"Piechotta V Andreas M Fischer AL Estcourt LJ Monsef I Fichtner F Antiplatelet agents for the treatment of COVID-19 (part of German Ecosystem CEO-Sys) www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021256351 2021"},{"issue":"9","key":"10.1002\/14651858.CD015078-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015395.pub2","article-title":"Nirmatrelvir combined with ritonavir for preventing and treating COVID-19","author":"Reis","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015078-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2022.23257","article-title":"Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial","volume":"329","author":"REMAP-CAP Writing Committee for the REMAP-CAP Investigators","year":"2023","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015078-BIB0083|cit83","unstructured":"Review Manager Web (RevMan Web) Cochrane 2022"},{"issue":"3","key":"10.1002\/14651858.CD015078-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000029.pub3","article-title":"Oral antiplatelet therapy for acute ischaemic stroke","author":"Sandercock","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015078-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015078-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015078-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD015078-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013665","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease","author":"Struyf","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015078-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"11","key":"10.1002\/14651858.CD015078-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014963.pub2","article-title":"Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence","author":"Wagner","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015078-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ajem.2021.01.016","article-title":"Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis","volume":"43","author":"Wang","year":"2021","journal-title":"The American Journal of Emergency Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015078-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD015078-BIB0093|cit93","unstructured":"World Health Organization Update on Omicron www.who.int\/news\/item\/28-11-2021-update-on-omicron 2021"},{"key":"10.1002\/14651858.CD015078-BIB0094|cit94","unstructured":"World Health Organization COVID-19 Clinical management: living guidance, 25 January 2021 apps.who.int\/iris\/handle\/10665\/338882"},{"key":"10.1002\/14651858.CD015078-BIB0095|cit95","unstructured":"World Health Organization Draft landscape of COVID-19 candidate vaccines www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"10.1002\/14651858.CD015078-BIB0096|cit96","unstructured":"World Health Organization WHO Coronavirus Disease (COVID-19) Dashboard covid19.who.int"},{"key":"10.1002\/14651858.CD015078-BIB0097|cit97","unstructured":"Therapeutics and COVID-19: Living guideline www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2023.1"},{"key":"10.1002\/14651858.CD015078-BIB0098|cit98","unstructured":"World Health Organization Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19) www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report"},{"key":"10.1002\/14651858.CD015078-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"100883","DOI":"10.1016\/j.cegh.2021.100883","article-title":"The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis","volume":"12","author":"Wijaya","year":"2021","journal-title":"Clinical Epidemiology and Global Health"},{"key":"10.1002\/14651858.CD015078-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1002\/14651858.CD015078-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001272.pub2","article-title":"Antiplatelet agents for intermittent claudication","author":"Wong","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015078-BIB0102|cit102","unstructured":"GNI per capita, Atlas method (current US$) https:\/\/data.worldbank.org\/indicator\/NY.GNP.PCAP.CD"},{"issue":"13","key":"10.1002\/14651858.CD015078-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:18:01Z","timestamp":1747790281000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015078"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":103,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015078","relation":{},"ISSN":["1465-1858"],"issn-type":[{"type":"electronic","value":"1465-1858"}],"subject":[],"published":{"date-parts":[[2023,7,25]]}}}